^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD52 expression

    i
    Other names: CD52, CD52 Molecule, HE5, EDDM5, CDW52, Human Epididymis-Specific Protein 5, CD52 Antigen (CAMPATH-1 Antigen), Epididymal Secretory Protein E5, Cambridge Pathology 1 Antigen, CAMPATH-1 Antigen, Epididymis Secretory Sperm Binding Protein Li 171mP, CDW52 Antigen (CAMPATH-1 Antigen), CD52 Antigen, HEL-S-171mP, CDw52, He5
    Entrez ID:
    1043
    Related biomarkers:
    Expression
    29d
    Universal CAR cell therapy: Challenges and expanding applications. (PubMed, Transl Oncol)
    In addition, the limited efficacy of T cells and NK cells against solid tumors is being addressed through CAR-Macrophages. In summary, CAR cell therapy has evolved to accommodate multiple cell types while expanding applications to various diseases, including hematologic malignancies and solid tumors, which holds tremendous growth potential and is promised to improve the lives of more patients in the future.
    Review • Journal • IO biomarker
    |
    CD52 (CD52 Molecule)
    |
    CD52 expression
    9ms
    Integrated Analysis of Single-Cell and Bulk RNA Sequencing Data Reveals Memory-like NK Cell Subset Associated with Mycobacterium tuberculosis Latency. (PubMed, Cells)
    These data were validated by flow cytometry analysis in a small cohort of samples, showing that LTBI subjects have a significant expansion of NK cells characterized by the prevalence of memory-like CD52+ NKG2C+ NK cells. Altogether, our results provide some new information on the role of NK cells in protective immune responses to Mtb.
    Journal
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD52 (CD52 Molecule) • KLRC2 (Killer Cell Lectin Like Receptor C2)
    |
    CD52 expression
    10ms
    Neoadjuvant chemotherapy-induced remodeling of human hormonal receptor-positive breast cancer revealed by single-cell RNA sequencing. (PubMed, Cancer Lett)
    In addition, we have identified novel genomic and transcriptional patterns of chemoresistant cancer cells, both innate and acquired, and have confirmed their prognostic value with TCGA cohorts. By shedding light on the ecosystem of HR + BC reshaped by chemotherapy, our results uncover valuable candidates for predicting chemosensitivity and overcoming chemoresistance in HR + BC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • LMNA (Lamin A/C) • CD4 (CD4 Molecule) • BTLA (B And T Lymphocyte Associated) • CD52 (CD52 Molecule) • KLRC1 (Killer Cell Lectin Like Receptor C1) • VSIR (V-Set Immunoregulatory Receptor)
    |
    HR positive • CD8 expression • CD52 expression
    12ms
    CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma. (PubMed, Pigment Cell Melanoma Res)
    CD52 expression is associated with features of ICB response in melanoma. Concomitant ICB and anti-CD52 treatment requires critical review.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
    |
    CD52 (CD52 Molecule)
    |
    CD52 expression
    12ms
    DISSECTING THE AGGRESSIVENESS OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA HARBORING T(14;19) FROM A CLINICAL-MOLECULAR PERSPECTIVE. AN ERIC AND ITALIAN CAMPUS CLL STUDY (SIE 2023)
    The aberrant expression of CD52 and CD274 might be an interesting hint to pursue innovative therapies for this aggressive subset of CLL. Figure 1.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • IGH (Immunoglobulin Heavy Locus) • TNFAIP3 (TNF Alpha Induced Protein 3) • CD52 (CD52 Molecule) • TP63 (Tumor protein 63) • BCL3 (BCL3 Transcription Coactivator)
    |
    CD8 expression • BCL3 overexpression • CD52 expression • TS 12
    over1year
    Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath (clinicaltrials.gov)
    P2, N=8, Completed, Goethe University | N=25 --> 8
    Enrollment change • Minimal residual disease
    |
    CD52 (CD52 Molecule)
    |
    CD52 expression
    |
    Campath (alemtuzumab) • cladribine
    almost2years
    CD52 EXPRESSION ON T CELLS PREDICT DEVELOPMENT OF ACUTE GVHD IN PATIENTS AFTER ALEMTUZUMAB BASED CONDITIONING (EBMT 2023)
    Patients were treated with RIC: fludarabine (30 mg/m2 days -7 to -3), melphalan (140 mg/m2 day 2) and alemtuzumab (20 mg days -8 to -4). For all three T cell subgroups, CD52 expression at day + 50 has at least excellent predicitive value. CD52 expression could be useful and an easy to analyze marker for the prediction of aGVHD after alemtuzumab. CD52 expression may lead to a more indiviualized strategy in tapering of immunosuppressive drugs.
    Clinical
    |
    CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • CD52 (CD52 Molecule) • FOXP3 (Forkhead Box P3)
    |
    CD52 expression
    |
    Campath (alemtuzumab) • melphalan • fludarabine IV